Form 4: McKesson Director Donald Knauss Receives Annual Equity Grant

McKesson Corp Director Donald R. Knauss was granted 469 Restricted Stock Units (RSUs) as part of an annual compensation plan, vesting immediately but deferring share receipt until board departure.

Summary

• Donald R. Knauss, a Director of McKesson Corp, received an annual grant of Restricted Stock Units (RSUs) on July 30, 2025.
• The grant consisted of two tranches: 301 RSUs and an additional 168 RSUs for his role as Chairman of the Board, totaling 469 RSUs.
• These RSUs were granted under the company's 2022 Stock Plan.
• The RSUs vest immediately upon grant, but the actual receipt of the underlying common shares is deferred until Mr. Knauss leaves the Board.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive action of aligning director incentives with shareholder value through equity compensation. It does not contain negative news or significant risks beyond the inherent market risk of holding equity.

Positives

• Grants align director's interests with long-term shareholder value through equity compensation.
• Immediate vesting of RSUs provides certainty of ownership, albeit with deferred share receipt.

Negatives

• No immediate cash flow for the director from these grants, as share receipt is deferred.

Risks

• Value of RSUs is tied to McKesson's common stock performance, exposing the director to market fluctuations until shares are received.

Future Outlook

The filing details a routine equity compensation grant to a director, indicating ongoing alignment of management incentives with long-term company performance. The deferral of share receipt until board departure suggests a mechanism to encourage continued service.

Industry Context

Equity compensation, particularly through Restricted Stock Units (RSUs), is a standard practice in the healthcare distribution and services industry, including large players like McKesson, to attract, retain, and incentivize directors and executives. This grant is consistent with typical corporate governance practices for director compensation.

Comparison to Industry Standards

• The use of RSUs with deferred share delivery is a common compensation structure for non-employee directors across various industries, including healthcare, to promote long-term alignment with shareholder interests and encourage board stability.
• Comparable companies in the pharmaceutical and healthcare distribution sector, such as Cardinal Health (CAH) and AmerisourceBergen (ABC), also frequently utilize equity-based compensation plans for their directors and executives, often including RSUs with similar vesting and deferral provisions.
• The grant size of 469 RSUs for a director, including an additional amount for the Chairman role, appears to be within the typical range for a company of McKesson's size and market capitalization, though specific benchmarks would require detailed compensation peer group analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are further aligned with the director through equity compensation, potentially encouraging long-term strategic decisions.
• Employees: No direct impact mentioned, but reflects standard executive/director compensation practices.

Next Steps

• Receipt of underlying common shares by Donald R. Knauss upon his departure from the McKesson Board.

Key Dates

Keywords

McKesson, MCK, Form 4, Insider Trading, Restricted Stock Units, RSUs, Equity Compensation, Director Compensation, Donald Knauss